Use of Anticoagulant Reversal Agents
|
|
- Sybil Mosley
- 6 years ago
- Views:
Transcription
1 Use of Anticoagulant Reversal Agents Lori Shutter, MD Vice Chair of Education Director, Neurocritical Care Program Professor, Critical Care Medicine, Neurology & Neurosurgery University of Pittsburgh Medical Center
2 Disclosures Disclosures: No financial disclosures
3 Objectives Compare DOACs Review the role of PCCs, FFP, vitamin K, and DOAC inhibitors Discuss acceptable INR values Manage patients on antiplatelet agents Determine timing of restarting anticoagulation following ICH
4 Platelet and Coagulation Disorders in the ICU N Engl J Med 2014;370:
5 Reversal of Anticoagulation: Basics Discontinue warfarin; Target INR < 1.5 It may be difficult to achieve with FFP & vit K FFP ml / kg Vitamin K, 10 mg IV. Usually only need 2-3 doses Prothrombin Complex Concentrate Recombinant Factor VIIa (selected patients?) If PTT > 50 Protamine 50 mg IV Platelet dysfunction Thrombelastography testing
6 TEG Thrombelastography technology analyzes functional activities of blood Coagulation & fibrinolytic factors, activators, inhibitors TEG ; Haemonetics Corp Components R value = time until first evidence of a clot K value = time from the end of R until the clot reaches 20mm (speed of clot formation) Angle = tangent of curve made as the K is reached and offers similar information to K MA (maximum amplitude) = reflection of clot strength
7 TEG Value Normal Range R 4 8 min k 0 4 min angle deg MA mm
8
9 Perioperative DOAC Discontinuation van Ryn et al. [2010], Spyropoulos & Douketis [2012], Baumann Kreuziger et al. [2012]. Ther Adv in Drug Safe. 2014;5(1):8-20.
10 DOACs and Lab Tests Palladino, et. Al., Am J Hematol 2012;87(suppl 1):s
11 Pharmacokinetic Comparison of Reversal Agents Anticoagulation Reversal Pharmacokinetics Agent Onset Duration Rebound of Anticoagulant Vitamin K 2 8 hours Days for INR Dose-dependent FFP 1 4 hours 6 hours 4 6 hours PCC minutes hours ~ 12 hours rfactor VIIa 10 minutes 4 6 hours 6 12 hours Am J Health-Syst Pharm. 2013; 70 (Suppl1):21-31.
12 Fresh frozen plasma (FFP) MOA Dose Onset of Effect Duration of Effect Advantages Disadvantages Replenishes clotting factors ml/kg, each bag administered over min minutes 20 to 24 hours Contains all clotting factors Low thrombotic risk Fast onset after administration Large volume typically needed Delay in administration due to matching, thawing, & administration Lowest INR achievable with FFP: Int J Stroke 2011;6:228-40
13 Prothrombin complex concentrate MOA Dose Onset 3-Factor PCC: Replenishes clotting factor II, IX, and X 4-Factor PCC: Replenishes clotting factors II, VII, IX, and X units/kg IV push over minutes Dosed on factor IX; variable dosing recs; round to vial size, administered no faster than 10 ml/min Onset: 10 minutes Duration of Effect Advantages Disadvantages Duration: 12 to 24 hours More evidence Less thrombosis risk Sustained effects Repletes all vitamin K dependent clotting factors Cost Controversial dosing 3-factor versus 4-factor?
14 Prothrombin Complex Concentrates Available in the United States 3- Factor PCCs Factors Covered (International Units relative to Factor IX)* II VII IX X Profilnine Bebulin VH # Factor PCCs Kcentra # & *Approximate values; exact potency of factors varies per vial; # contains heparin, & protein C and S. **20 50 u/kg of 4-Factor PPC = 8 16 units FFP!!!! Sorenson B, et al. Crit Care 2011;15:201. Kcentra package insert. Kankakee, IL: CSL Behring; 2013
15 Kcentra Dosing: Warfarin Reversal (FDA approved) Dosed on actual body weight up to 100 kg Max rate of IV administration: 8.4 ml/min (210 U/min) Do not mix, separate line for admin
16 What if the INR is < 2? 21/134 patients presented with traumatic (43%) or spontaneous (57%) bleeding. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0 Neuocrit Care Dec;27(3):
17 INCH Trial: VKA ICH Lancet Neurol 2016; 15:
18 INCH Trial: VKA ICH Lancet Neurol 2016; 15:
19 Hematoma Expansion Lancet Neurol 2016; 15:
20 Reversal Agent Potential for Success AGENT 4-factor PCC DOSES TESTED IN STUDIES IU/kg (50 IU/kg is only doses tested in humans DABIGATRAN Not beneficial RIVAROXABAN/ APIXABAN Probably beneficial apcc (FEIBA) IU/kg Not beneficial Probably beneficial Factor VIIa mcg/kg Not beneficial Possibly beneficial FFP N/A Probably ineffective Probably ineffective 3-factor PCC No data No data No data Activate Charcoal/ HD In Vitro/volunteers Possibly beneficial if given <2 hrs/yes Possibly beneficial if given <2 hrs/no Lazo-Langner A, Lang ES, Douketis J. Clinical Review: Clinical management of new oral Anticoagulants: a structured review with emphasis on the reversal of bleeding complications Critical Care. 2013; 17:
21 DOAC Antidotes Am J Health-Syst Pharm. 2016; 73(suppl 2):S5-13
22 Idarucizumab (Praxbind ) Dabigatran Reversal Accelerated FDA APPROVAL 10/16/15 Dose: 5 g IV 2 separate consecutive infusions 2.5g/50 ml vials Limited data for repeat dosing ADRS: hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, acute liver failure Can reinitiate dabigatran 24 hours after infusion
23 FXa Inhibitor Antidote Andexanet alfa under FDA review PRT064445; Portola Pharmaceuticals, An imitation factor Xa without biological properties Reverses the anticoagulant action of the factor Xa inhibitors Crowther M, et al. AHA 2014 Scientific Sessions; November 15-19, 2014; Chicago, IL. J Thromb Haemost 2016;14:
24 Considerations in patients with Major Bleeding or Emergent Surgery Pharmacologic Identification of specific DOAC and dose Time elapsed since last dose Renal function Determining half-life of DOAC Liver function and signs of coagulopathy Specific anticoagulation test or if not available screening test (aptt, pro-thrombin time, and anti-fxa activity) Clinical Signs of hemodynamic instability Identification of bleeding source Reason for emergency surgery Assessment of thromboembolic (CHA2DS2-VASc) and bleeding risk (HAS- BLED) Eur Heart J. 2017;38(22):
25 When are antidotes indicated? Life-threatening bleeding Bleeding into a critical organ or closed space Prolonged bleeding despite local hemostatic measures High risk of recurrent bleeding because of overdose or delayed clearance of DOACs Need for an urgent intervention associated with a high risk of bleeding Emergency surgery or intervention in patients at high risk for procedural bleeding: Neurosurgery (intracranial, extradural,or spinal), lumbar puncture, cardiac or vascular surgery (aortic dissection/aneurysm repair), hepatic or other major organ surgery Levy J, et al. Journal of Thrombosis and Haemostasis, 14:
26 When should antidotes NOT Be Used? Elective surgery Bleeding managed with local hemostatic measures Bleeding has stopped Interventions can be delayed 8 h to permit clearance of effects Levy J, et al. Journal of Thrombosis and Haemostasis, 14:
27 Anticoagulation Reversal Guidelines Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46. European Heart Journal 2013;34:
28 VKA reversal: NCS Guidelines 2016 Treatment: Vit K 10 mg IV X 1 3- or 4-factor PCC for VKA-assoc ICH & INR > 1.4. (Strong recommendation, moderate quality evidence) INR min after dose, and serially every 6 8 h for the next h Subsequent treatment guided by follow-up INR Caution: repeat PCC dosing may lead to increased thrombotic complications and risk of DIC. (Good Practice statement) Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46.
29 Direct thrombin inhibitors Assess time & amount of last ingested dose, renal function, and possible medication interactions to assist in estimating the degree of anticoagulation exposure. (Good Practice statement) Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46.
30 Direct thrombin inhibitors Treatment: Activated charcoal if within 2 hrs of oral dose Idarucizumab (5 g IV in two divided doses) to patients with ICH if within 3-5 t ½ s or renal dysfunction or failure If idarucizumag not available: 4-PCC (50 IU/kg) > 3-PCC; apcc (FEIBA) 50 IU/KG Hemodialysis (up to 60% dabigatran removed) Monitoring Assess for clinically significant bleeding Thrombin time (TT) Ecarin clotting time (ECT) Activated partial thromboplastin time (aptt) Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46.
31 Factor Xa inhibitors Obtain information re: time elapsed since last dose of direct factor Xa inhibitor & possible medication interactions to assist in estimating the degree of anticoagulation exposure. (Good Practice statement) Treatment Activated charcoal if within 2 hrs of oral dose 4-PCC (50 IU/kg); 3-PCC; apcc IF ICH <3-5 t ½ s or liver failure Monitoring Assess for clinically significant bleeding Anti-Xa activity; Specific chromogenic anti-factor Xa assay Prothrombin time (PT) Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46.
32 Heparin MOA: Enhances antithrombin III activity while inactivating thrombin and prevents the conversion of fibrinogen to fibrin Low Molecular Weight Heparinoids MOA: Enhances antithrombin III activity while inactivating thrombin which prevents the conversion of fibrinogen to fibrin and inhibits factor Xa
33 PROTAMINE MOA Dose Administration Heparin Reversal Combines with heparin to form a stable complex that neutralizes anticoagulant activity Protamine 1 mg / 1 mg of enoxaparin given in previous 8 hrs Max dose of 50 mg over 10 min Faster infusions cardiovascular collapse; Excessive doses (>100 mg) may worsen bleeding by acting as an anticoagulant LMWH Reversal Onset of Effect ~ 5 minutes ~ 5 minutes Advantages Disadvantages Rapid reversal of heparin portion in enoxaparin Does not affect factor Xa inhibition of LMWH mechanism Potential for rebound bleeding Hypersensitivity risk Combines with heparin to form a stable complex that neutralizes anticoagulant activity Protamine 1 mg / 100 units of heparin given in previous 2-3 hrs Max dose of 50 mg over 10 min Faster infusions cardiovascular collapse); Excessive doses (>100 mg) may worsen bleeding by acting as an anticoagulant Rapid and predictable reversal of heparin Potential for rebound bleeding (8-18 hrs after dose) Hypersensitivity risk (hypotension), PROTAMINE PI especially in pts with a fish allergy
34 ANTIPLATELET REVERSAL AFTER ICH PATCH Trial
35 Antiplatelet Reversal in ICH Receipt of antiplatelet agents prior to ICH or traumatic bleeding is associated with worse outcomes Medications for reversing platelet function (eg. DDAVP) incompletely effective No rigorous clinical study to actually support giving platelet transfusion for patients with antiplatelet exposure prior to ICH Other examples of continued coagulopathy suggest potential for hematoma expansion after ICH
36 PATCH Trial Platelet transfusion initiated within 6 hours of symptom onset Patients with non-traumatic supratentorial ICH Glasgow Coma Score 8-15 Receipt of ASA, clopidogrel or dipyridamole within 7 days of presentation Patients with planned ICH evacuation were excluded Platelet transfusion (1-ASA, 2-clopidogrel) No platelet transfusion Baharoglu MI, et al. Lancet 2016; 387:
37 Key PATCH Trial Results ~78% of patients received ASA prior to admission Median admission GCS was ~70% of ICH were deep supratentorial Basal ganglia or thalamic ICH Median ICH volume was ~10ml Adverse events 42% transfusion vs 29% standard care (OR 1.74, 95%CI ) Baharoglu MI, et al. Lancet 2016; 387:
38 Key PATCH Trial Results Primary outcome was worse in transfusion group Death or dependence at 3 months Adjusted OR 2.05, 95%CI , p = Baharoglu MI, et al. Lancet 2016; 387:
39 In which antiplatelet-associated ICH patients should platelet transfusion still be considered? Patients receiving clopidogrel (?) Under-represented in PATCH Patients requiring CNS procedures EVD Operation for hematoma evacuation Patients with traumatic ICH
40 Antiplatelet Agent (APA) Reversal NCS Recommendations Discontinue antiplatelet agent (Good Practice statement) Suggest against platelet transfusion for patients with APA associated ICH who will NOT undergo a neurosurgical procedure, regardless of the type of platelet inhibitor, platelet function testing, hemorrhage volume, or neurological exam. (Conditional recommendation, low-quality evidence) Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46. European Heart Journal 2013;34:
41 APA Reversal NCS Recommendations Suggests platelet transfusion for patients with aspirinor ADP inhibitor- associated ICH who will undergo a neurosurgical procedure. (Conditional recommendation, moderate quality of evidence) Platelet function testing prior to platelet transfusion if possible. (Strong rec, moderate quality evidence) When platelet function testing is not readily available, empiric platelet transfusion may be reasonable. (Conditional rec, low quality evidence) Recommend against platelet transfusion for patients with laboratory documented platelet function within normal limits or documented antiplatelet resistance. (Strong recommendation, moderate quality evidence) Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46. European Heart Journal 2013;34:
42 APA Reversal NCS Recommendations Suggests against platelet transfusion in NSAID or GP IIb/IIIa inhibitor-related ICH, even in the context of neurosurgical intervention. (Conditional recommendation, very low-quality evidence) Suggests consideration of a single dose of desmopressin (DDAVP) in ICH (0.4 mcg/kg IV) associated with aspirin/cox-1 inhibitors or ADP receptor inhibitors. In patients deemed appropriate (e.g., those undergoing a neurosurgical procedure), DDAVP can be used in addition to platelet transfusion (Conditional recommendation, low-quality evidence) Frontera J et al, Neurocrit Care 2016; Feb;24(1):6-46. European Heart Journal 2013;34:
43 When can you resume coagulation? Wish I knew Varies patient to patient Factors: Risk of stroke Risk of bleeding
44 Antithrombotic Reversal Strategies: Summary DOACs have variable kinetic characteristics that cause variable anticoagulant effects. Indications for reversal should be identified before any reversal strategy is initiated. Determination the last dose of the DOAC is crucial 4PCC are recommended for OACs that do not have antidotes available. Idarucizumab is currently FDA approved and available for dabigatran reversal. Platelets may worsen outcomes and should only be administered in life threatening bleeding situations where benefit > risk.
45 UPMC Critical Care
ADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationManaging Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants
Managing Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants MICHAEL E. MULLINS MD FAACT FACEP Washington University School Of Medicine Chair, BJH Anticoagulation Subcommittee Chair,
More informationREVERSAL STRATEGIES FOR ORAL ANTICOAGULATION
REVERSAL STRATEGIES FOR ORAL ANTICOAGULATION Wesley R. Zemrak, Pharm.D., BCPS Clinical Pharmacy Specialist, Anticoagulation Maine Medical Center, Portland, ME zemraw@mmc.org 1 OBJECTIVES 1. Discuss the
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS
ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, THROMBOLYTIC REVERSAL IN ADULT PATIENTS Several of the below interventions are based on low-level evidence and are intended as suggestions only.
More informationManaging Bleeding on NOACs
Managing Bleeding on NOACs and Other Evolving ED Protocols Objectives Understand that NOACs are widely used in clinical practice Discuss the new and evolving protocols for managing bleeding in patients
More informationUPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center
UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center DISCLOSURE STATEMENT OF FINANCIAL INTEREST I, Vera Wilson,
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationReversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding
Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)
More informationLeading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient
Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationGuideline for Treatment of Head Injury in the Anticoagulated Patient
Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationThis quiz is being published on behalf of the Education Committee of the SNACC.
Shobana Rajan, M.D. Staff Anesthesiologist, Cleveland Clinic, Cleveland, Ohio Quiz team; Shaheen Shaikh, M.D; Suneeta Gollapudy,M.D; Verghese Cherian, M.D This quiz is being published on behalf of the
More informationBLOOD DISEASE RESEARCH FOUNDATION
BLOOD DISEASE RESEARCH FOUNDATION BLOOD DISEASE RESEARCH FOUNDATION The mission of Blood Disease Research Foundation is to support hematological research, e.g. by donating grants for thesis work and abstract
More informationAgent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min
Nanik (Nayri) Hatsakorzian Pharm.D/MPH candidate 2014 Touro University College of Pharmacy CA Bleeding Reversal Agents Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes
More informationEverything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science
Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Center at San Antonio Department of Pharmacotherapy
More informationTreatment of anticoagulant-associated intracerebral haemorrhage
Treatment of anticoagulant-associated intracerebral haemorrhage Adrian Parry-Jones NIHR Clinician Scientist & Honorary Consultant Neurologist Manchester Academic Health Science Centre, Salford Royal NHS
More informationIntroduction. Blood Pressure
Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and
More informationDirect Oral Anticoagulant Reversal
08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationEmergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies
AACN Advanced Critical Care Volume 25, Number 1, pp. 5-12 2014 AACN ECG Challenges Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Emergent Reversal of Oral Anticoagulation:
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationNew Options for Anticoagulation Reversal: A Practical Approach
New Options for Anticoagulation Reversal: A Practical Approach Hyung Wook Park Chonnam National University Hospital, Gwangju, Korea 4 NOACs Prevention of TE No. of events (%/yr..) NOAC Warfarin HR 95%
More informationEndoscopy and the Anticoagulated Patient
Endoscopy and the Anticoagulated Patient John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Objectives To accurately assess the risk
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More information7/6/ ANNUAL MEETING CURRENT REVERSAL STRATEGIES FOR ORAL ANTICOAGULANTS AND A LOOK AT NEW REVERSAL AGENTS PHARMACY TECHNICIAN OBJECTIVES
PHARMACY TECHNICIAN OBJECTIVES Identify brand/generic names of medications used for oral anticoagulation CURRENT REVERSAL STRATEGIES FOR ORAL ANTICOAGULANTS AND A LOOK AT NEW REVERSAL AGENTS PRESENTED
More informationCoagulation BEFORE Surgery
Coagulation BEFORE Surgery Lorenzo ALBERIO Médecin chef Hématologie générale et Hémostase Service et Laboratoire centrale d Hématologie CHUV, Lausanne Outline 1. Pre-op testing 2. Ongoing anticoagulation
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationReversal of DOACs Breakthroughs and Their Aftermath
Reversal of DOACs Breakthroughs and Their Aftermath Geno J Merli, MD, MACP, FSVM, FHM Professor Medicine & Surgery Co-Director Jefferson Vascular Center Sidney Kimmel Medical College Thomas Jefferson University
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationAnticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016
Review Article in Major Bleeding: Update 2016 Steve Christos, DO, MS* Robin Naples, MD * Presence Resurrection Medical Center, Department of Emergency Medicine, Chicago, Illinois Lewis Katz School of Medicine
More informationOverview of the Direct Oral Anticoagulants
Original Article Nedaa Skeik, MD Abhishek Sethi Michele Shepherd, PharmD From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Nedaa Skeik, MD Minneapolis
More informationIdarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):
Idarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):511-520. Objective: To measure the safety of idarucizumab to reverse dabigatran anticoagulant effects
More informationANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital
ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity
More informationReversal of Oral Anticoagulation in Critical Care. Andrew C. Faust, PharmD, BCPS Critical Care Pharmacy Specialist Texas Health Presbyterian Dallas
Reversal of Oral Anticoagulation in Critical Care Andrew C. Faust, PharmD, BCPS Critical Care Pharmacy Specialist Texas Health Presbyterian Dallas Conflicts of Interest No conflicts to report Objectives
More informationA Cascade of Updates: Hot Topics in Anticoagulation
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY
ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY Click here for the full Thrombosis Prevention Investigation and Management of Anticoagulation Guideline Click on the appropriate link below: o START
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationFaculty. DOACs and Reversal Agents: Disclosures. Considerations for Health-System Pharmacists. Learning Objectives
Faculty DOACs and Reversal Agents: Considerations for Health-System Pharmacists Mark A. Munger, PharmD, FCCP, FACC, FHFSA Professor of Pharmacotherapy Adjunct Professor, Internal Medicine University of
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationStolling en anesthesie. Erik Vandermeulen MD, PhD Dept. of Anesthesia
Stolling en anesthesie Erik Vandermeulen MD, PhD Dept. of Anesthesia Preoperative use of anticoagulation Vitamin K-antagonists (VKA) Fenprocoumon (Marcoumar ) Warfarin (Marevan ) Acenocoumarol (Sintrom
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More information10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI
10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationGUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS
GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS This guideline covers the management of patients being treated with Vitamin K antagonists (VKA): Warfarin Acenocoumarol
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationDisclosure and Conflict of Interest
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationNOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations
NOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations Mark J. Alberts, MD, FAHA Hartford HealthCare Hartford, CT USA AF confers an increased
More informationAndexanet alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding
Andexanet alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding Stuart J. Connolly, M.D., Truman J. Milling, Jr., M.D., John W. Eikelboom, M.D., C. Michael Gibson, M.D., John T. Curnutte, M.D., Ph.D.,
More informationA Brief History of the World of Anticoagulation
A Brief History of the World of Anticoagulation Allison Burnett, PharmD, CACP, PhC Clinical Assistant Professor- UNM College of Rx Antithrombosis Stewardship Pharmacist University of New Mexico Hospital
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationGuidelines for testing and perioperative management of dabigatran and rivaroxaban
Guidelines for testing and perioperative management of dabigatran and rivaroxaban: for possible use in local management protocols These guidelines have been produced by PHARMAC in conjunction with bpac
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationChoosing and Managing Direct Oral Anticoagulants (DOACs)
Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationMANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas
MANAGEMENT OF OVER-ANTICOAGULATION Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas Risk of Intracranial Hemorrhage in Outpatients (From Management of Oral Anticoagulant
More informationDr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust. North East RTC Annual Education Symposium 16 th October 2014
Dr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust North East RTC Annual Education Symposium 16 th October 2014 The extent of the problem 1-2% of the UK population are anticoagulated
More informationNovel Anticoagulants: Emerging Evidence
18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant
More informationPatients presenting with acute stroke while on DOACs
Patients presenting with acute stroke while on DOACs Vemmos Kostas, MD, PhD Stroke Medicine Hellenic Cardiovascular Research Society Conflicts of interest Honoraria and speaker fees from: BAYER, SANOFI,
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More informationICU. Recovery. Plus Ultrasound-guided mechanical ventilation, F. Mojoli & S. Mongodi MANAGEMENT & PRACTICE
ICU MANAGEMENT & PRACTICE VOLUME 17 - ISSUE 3 - AUTUMN 2017 CSL Behring Supplement from Euroanaesthesia 2017 Symposium Recovery The role of autophagy in the metabolism and outcomes after surgery, J. Gunst
More informationManagement of Challenging Bleeding: Patients with Coagulopathy
Management of Challenging Bleeding: Patients with Coagulopathy Joanne E Joseph Department of Haematology, SydPath St Vincent s Hospital University of NSW Sydney First and foremost.. It helps to know which
More information